SCHEMBL648247

SCHEMBL648247

CCCCn1c(-c2ccccc2)nc(C#N)c1CN(Cc1cccc(OCC)c1)Cc1ccc2c(c1)OCCO2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.47
ALDH1A1 P00352 3/20 0.37
MAPK1 P28482 2/20 0.37
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
MAPT P10636 3/20 0.36
HPGD P15428 2/20 0.36
TSHR P16473 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PTGDR2 Q9Y5Y4 2/20 0.36
CTSL P07711 2/20 0.35
HTT P42858 1/20 0.35
CYP2C8 P10632 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
BCHE P06276 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649789 0.95 C5AR1 (0.53) C5AR1ALDH1A1MAPK1MAPTHPGD
SCHEMBL650512 0.91 C5AR1 (0.55) C5AR1ALDH1A1MAPK1OPRM1OPRD1
SCHEMBL650376 0.91 C5AR1 (0.38) C5AR1ALDH1A1MAPK1OPRM1OPRD1
SCHEMBL650859 0.90 C5AR1 (0.51) C5AR1ALDH1A1MAPK1OPRM1OPRD1
SCHEMBL648633 0.89 C5AR1 (0.50) C5AR1ALDH1A1MAPK1OPRM1OPRD1
SCHEMBL648859 0.89 C5AR1 (0.56) C5AR1ALDH1A1MAPK1OPRM1OPRD1
SCHEMBL650088 0.89 HTR2A (0.37) C5AR1ALDH1A1MAPK1MAPTHPGD
SCHEMBL1913068 0.89 C5AR1 (0.49) C5AR1ALDH1A1MAPK1OPRM1OPRD1
SCHEMBL650062 0.89 C5AR1 (0.49) C5AR1ALDH1A1MAPK1OPRM1OPRD1
SCHEMBL650031 0.89 C5AR1 (0.49) C5AR1ALDH1A1MAPK1OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed